Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients

Joint Bone Spine

Volumn 82, Issue 3, 2015, Pages 187-191

  Iannone, Florenzo ^a   Fanizzi, Rosalinda ^a   Notarnicola, Antonella ^a   Scioscia, Crescenzio ^a   Anelli, Maria Grazia ^a   Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Adalimumab; Body mass; Etanercept; Infliximab; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT; REMISSION; RHEUMATOID ARTHRITIS; SURVIVAL; UNDERWEIGHT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPLICATION; DISEASE COURSE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929288125     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.12.006     Document Type: Article

References (23)

1. Iannone F., Lapadula G. Obesity and inflammation--targets for OA therapy. Curr Drug Targets 2010, 11:586-598.
2. Bhole V.M., Choi H.K., Burns L.C., et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012, 51:552-556.
3. Crowson C.S., Matteson E.L., Davis J.M., et al. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013, 65:71-77.
4. Ajeganova S., Andersson M.L., Hafström I., et al. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term follow-up from disease onset. Arthritis Care Res (Hoboken) 2013, 65:78-87.
5. Gremese E., Carletto A., Padovan M., et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 2013, 65:94-100.
6. Choe J.Y., Bae J., Lee H., et al. Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation. Clin Rheumatol 2014, 33:485-492.
7. Velpula U.D., Agrawal S., Thomas J., et al. Low body mass index is adversely associated with radiographic joint damage in Indian patients with early rheumatoid arthritis. J Rheumatol 2011, 38:434-438.
8. Westhoff G., Rau R., Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007, 56:3575-3582.
9. van der Helm-van Mil A.H., van der Kooij S.M., Allaart C.F., et al. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008, 67:769-774.
10. Baker J.F., Ostergaard M., George M., et al. Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2years. Ann Rheum Dis 2014, 73:1923-1928.
11. Rho Y.H., Solus J., Sokka T., et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009, 60:1906-1914.
12. Giles J.T., Allison M., Bingham C.O., et al. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009, 61:1248-1256.
13. Klaasen R., Wijbrandts C.A., Gerlag D.M., et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011, 63:359-364.
14. Sandberg M.E., Bengtsson C., Källberg H., et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 2014, 73:2029-2033.
15. Ellerby N., Mattey D.L., Packham J., et al. Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis 2014, 73:e74.
16. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
17. Jacobsson L.T., Hetland M.L. New remission criteria for RA: "modern times" in rheumatology--not a silent film, rather a 3D movie. Ann Rheum Dis 2011, 70:401-403.
18. Ottaviani S., Allanore Y., Tubach F., et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 2012, 14:R115.
19. di Minno M.N., Peluso R., Iervolino S., et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013, 65:141-147.
20. Iannone F., Fanizzi R., Scioscia C., et al. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Scand J Rheumatol 2013, 42:41-44.
21. Rodrigues A.M., Reis J.E., Santos C., et al. A1.1 Obesity is a risk factor for worse treatment response in rheumatoid arthritis patients- results from reuma.pt. Ann Rheum Dis 2014, 73:A1.
22. Heimans L., van den Broek M., le Cessie S., et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013, 65:1235-1242.
23. Iannone F., Gremese E., Atzeni F., et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012, 39:1179-1184.